AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11642426 — intervention group
Group type: EXPERIMENTAL
Intervention: Glottic reconstruction with false vocal fold (FVF) mucosal flap
Number of subjects: 0
Study 11642426 — intervention group
Group type: COMPARATOR
Intervention: Standard frontolateral partial laryngectomy (FLPL) without glottic reconstruction
Number of subjects: 0
Study 11907944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol delivery system A (twice a week)
Number of subjects: 20
Study 11907944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol delivery system B (once a week)
Number of subjects: 20
Study 11907944 — intervention group
Group type: COMPARATOR
Intervention: Both systems (A and B)
Number of subjects: 20
Study 8023719 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg o.m.)
Number of subjects: 448
Study 8023719 — intervention group
Group type: COMPARATOR
Intervention: Histamine H2-receptor antagonists (cimetidine 400 mg q.d.s. or ranitidine 150 mg b.d.)
Number of subjects: 448
Study 31880055 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP)
Number of subjects: 50
Study 31880055 — intervention group
Group type: COMPARATOR
Intervention: 37% carbamide peroxide (CP)
Number of subjects: 50
Study 29042091 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 58
Study 29042091 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 58
Study 27183546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) implants
Number of subjects: 0
Study 27183546 — intervention group
Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 0
Study 27183546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 µg/day FAc
Number of subjects: 0
Study 27183546 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication, trabeculoplasty, or surgery
Number of subjects: 0
Study 25625612 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 with balanced propofol sedation (BPS)
Number of subjects: 0
Study 25625612 — intervention group
Group type: COMPARATOR
Intervention: Air with balanced propofol sedation (BPS)
Number of subjects: 0
Study 25625612 — intervention group
Group type: COMPARATOR
Intervention: Air with propofol + opioid sedation (PS)
Number of subjects: 0
Study 25625612 — intervention group
Group type: COMPARATOR
Intervention: CO2 with propofol + opioid sedation (PS)
Number of subjects: 0
Study 23395927 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted total laparoscopic hysterectomy
Number of subjects: 53
Study 23395927 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy
Number of subjects: 53
Study 19631970 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 53
Study 19269130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine Safety Messages (VSM)
Number of subjects: 108
Study 19269130 — intervention group
Group type: COMPARATOR
Intervention: Vaccine Information Statement (VIS)
Number of subjects: 108
Study 17291166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 83
Study 17291166 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic relaxation training
Number of subjects: 83
Study 17291166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 83
Study 15064512 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental method using a 2.0 X magnifying lens mounted on a headband
Number of subjects: 44
Study 15064512 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of catheter insertion
Number of subjects: 44
Study 11593077 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of mifepristone
Number of subjects: 5
Study 11593077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9455695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (2 x 400 IU RRR‐alpha‐tocopherol/day) for 12 weeks
Number of subjects: 23
Study 9455695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E retreatment after cessation
Number of subjects: 23
Study 7947424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms with morphine 0.25 mg
Number of subjects: 30
Study 7947424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 10 micrograms with morphine 0.25 mg
Number of subjects: 30
Study 2452245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 134
Study 2452245 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin or Chloramphenicol
Number of subjects: 134
Study 30074402 — intervention group
Group type: EXPERIMENTAL
Intervention: Load of 4.5 kg
Number of subjects: 11
Study 30074402 — intervention group
Group type: EXPERIMENTAL
Intervention: Load of 9.0 kg
Number of subjects: 11
Study 30074402 — intervention group
Group type: EXPERIMENTAL
Intervention: Load of 13.5 kg
Number of subjects: 11
Study 27130868 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept MI
Number of subjects: 359
Study 27130868 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept LI
Number of subjects: 359
Study 27130868 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 359
Study 27130868 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 359
Study 27130868 — intervention group
Group type: COMPARATOR
Intervention: Belatacept and Cyclosporine
Number of subjects: 359
Study 26155841 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment navigators
Number of subjects: 40
Study 24011635 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (newly developed lamivudine tablet)
Number of subjects: 28
Study 24011635 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (branded lamivudine tablet)
Number of subjects: 28
Study 24011635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 28
Study 21119152 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment model
Number of subjects: 60
Study 21119152 — intervention group
Group type: COMPARATOR
Intervention: Conventional psychiatric out-patient care
Number of subjects: 60
Study 18480202 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz plus two NRTIs
Number of subjects: 757
Study 18480202 — intervention group
Group type: COMPARATOR
Intervention: lopinavir-ritonavir plus two NRTIs
Number of subjects: 757
Study 18480202 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir plus efavirenz (NRTI-sparing group)
Number of subjects: 757
Study 15898289 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate lotion
Number of subjects: 229
Study 15898289 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate emollient cream
Number of subjects: 229
Study 15898289 — intervention group
Group type: COMPARATOR
Intervention: Lotion vehicle
Number of subjects: 229
Study 12926095 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (EXE)
Number of subjects: 769
Study 12926095 — intervention group
Group type: COMPARATOR
Intervention: Megestrol Acetate (MA)
Number of subjects: 769
Study 10821298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral oestrogen (1 mg, 17-beta-estradiol)
Number of subjects: 34
Study 10821298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen (1 mg 17-beta-estradiol) in combination with low-dose (0.5 mg) continuous norethisterone acetate (NETA)
Number of subjects: 34
Study 10821298 — intervention group
Group type: COMPARATOR
Intervention: Control group (Low-dose oral oestrogen)
Number of subjects: 34
Study 10821298 — intervention group
Group type: COMPARATOR
Intervention: Control group (Oestrogen with NETA)
Number of subjects: 34
Study 9007160 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (dose-dependent)
Number of subjects: 0
Study 9007160 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors (control)
Number of subjects: 0
Study 1387445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 2
Study 1387445 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate/ranitidine
Number of subjects: 2
Study 6573807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2 alpha
Number of subjects: 0
Study 6573807 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2
Number of subjects: 0
Study 6573807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 6573807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prostaglandin F2 alpha and E2
Number of subjects: 0
Study 31410633 — intervention group
Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I) at therapeutic doses
Number of subjects: 0
Study 31410633 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-QT model
Number of subjects: 0
Study 29634661 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART initiation (N=408)
Number of subjects: 816
Study 29634661 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART initiation (N=408)
Number of subjects: 816
Study 29634661 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic pressure >140mmHg at enrolment
Number of subjects: 816
Study 29634661 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic pressure <90mmHg at enrolment
Number of subjects: 816
Study 29634661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent and incident hypertension
Number of subjects: 816
Study 26359184 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min of moderate physical activity every school day (intervention)
Number of subjects: 3534
Study 26359184 — intervention group
Group type: COMPARATOR
Intervention: Swedish standard curriculum of 60 min of physical activity per school week (control)
Number of subjects: 3534
Study 24666591 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component multidisciplinary collaborative intervention
Number of subjects: 20
Study 24666591 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 22361211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored postal feedback on prescribing of acamprosate
Number of subjects: 115
Study 22361211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored postal feedback on prescribing of naltrexone
Number of subjects: 115
Study 22361211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored postal feedback intervention
Number of subjects: 115
Study 19505812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation of docosahexaenoic acid (DHA) at levels close to 0.32%
Number of subjects: 0
Study 19505812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation of arachidonic acid (ARA) at levels of at least 0.3%
Number of subjects: 0
Study 19505812 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas providing close to the worldwide human milk mean of 0.32% DHA
Number of subjects: 0
Study 19505812 — intervention group
Group type: COMPARATOR
Intervention: Control group (formula-fed infants without DHA and ARA supplementation)
Number of subjects: 0
Study 18065583 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/d (800 IU/d) vitamin D(3)
Number of subjects: 208
Study 18065583 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/d (2000 IU/d) vitamin D(3)
Number of subjects: 208
Study 18065583 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for prescribing vitamin D
Number of subjects: 208
Study 15110729 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually spoken words (video of a talker's utterance without audio)
Number of subjects: 0
Study 15110729 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual speech primes
Number of subjects: 0
Study 15110729 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition priming effect
Number of subjects: 0
Study 15110729 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming found in all tasks
Number of subjects: 0
Study 11214131 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUS
Number of subjects: 236
Study 11214131 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study 9761130 — intervention group
Group type: EXPERIMENTAL
Intervention: I2 (iodine) at doses of 0.3 or 1 mg/kg body weight
Number of subjects: 33
Study 9761130 — intervention group
Group type: EXPERIMENTAL
Intervention: I- (iodide) at doses of 0.3 or 1 mg/kg body weight
Number of subjects: 33
Study 9761130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 7531032 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic therapy (EST) with low voltage (200 to 1200 V)
Number of subjects: 15
Study 7531032 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic therapy (EST) with high voltage (500 to 2500 V)
Number of subjects: 15
Study 7531032 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic therapy (EST) with high voltage together with high magnetic field
Number of subjects: 15
Study 3139379 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms twice daily
Number of subjects: 416
Study 3139379 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 200 micrograms four times daily
Number of subjects: 416
Study 31606903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin-containing oligomeric formula (POF)
Number of subjects: 201
Study 31606903 — intervention group
Group type: COMPARATOR
Intervention: Standard polymeric formula (SPF)
Number of subjects: 201
Study 31129386 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 162
Study 31129386 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + panitumumab (6 mg/kg)
Number of subjects: 162
Study 31129386 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + rilotumumab (10 mg/kg)
Number of subjects: 162
Study 29087166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence packaging intervention group
Number of subjects: 240
Study 29087166 — intervention group
Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 240
Study 29087166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 240
Study 27444426 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administration of the TAPS Tool
Number of subjects: 2000
Study 27444426 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of the TAPS Tool
Number of subjects: 2000
Study 27444426 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPS Tool
Number of subjects: 2000
Study 24557022 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg bolus and continuous infusion of 16 mg/kg/h (Group HIGH)
Number of subjects: 33
Study 24557022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg bolus followed by 5 mg/kg/h (Group LOW)
Number of subjects: 33
Study 24557022 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (Placebo)
Number of subjects: 33
Study 22385927 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 47
Study 22385927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19456308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diazepam (DZP) 5 mg
Number of subjects: 0
Study 19456308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (MDZ) 5 mg
Number of subjects: 0
Study 19456308 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (DZP)
Number of subjects: 0
Study 19456308 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (MDZ)
Number of subjects: 0
Study 17890994 — intervention group
Group type: EXPERIMENTAL
Intervention: Group academic detailing with physician-level performance feedback
Number of subjects: 38
Study 17890994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 15272537 — intervention group
Group type: EXPERIMENTAL
Intervention: hASH1 mRNA levels in esthesioneuroblastomas
Number of subjects: 24
Study 15272537 — intervention group
Group type: COMPARATOR
Intervention: hASH1 mRNA levels
Number of subjects: 24
Study 11354393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10% response rate)
Number of subjects: 24
Study 11354393 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drug (70% response rate)
Number of subjects: 24
Study 11354393 — intervention group
Group type: COMPARATOR
Intervention: Investigational drug (70% response) vs Standard therapy (60% response)
Number of subjects: 24
Study 10465074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lymph node needle aspiration
Number of subjects: 6
Study 10465074 — intervention group
Group type: COMPARATOR
Intervention: Standard excisional biopsy
Number of subjects: 6
Study 7598872 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite myo-mucosal reconstruction of the vocal fold using a muscular flap and free mucosal transplant
Number of subjects: 11
Study 2190897 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 150 mg b.i.d. p.o. for ten days
Number of subjects: 210
Study 2190897 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg b.i.d. p.o. for ten days
Number of subjects: 210
Study 24401 — intervention group
Group type: EXPERIMENTAL
Intervention: LS-bicarbonate dialysis
Number of subjects: 0
Study 24401 — intervention group
Group type: COMPARATOR
Intervention: LS-carbonate dialysis
Number of subjects: 0
Study 30918030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention programme (weekly group sessions for 12 months)
Number of subjects: 96
Study 28124514 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 32
Study 28124514 — intervention group
Group type: COMPARATOR
Intervention: Sham-RIPC
Number of subjects: 32
Study 24733234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function measured by the Trail Making Test in people with COPD
Number of subjects: 0
Study 24733234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 0
Study 24733234 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, education, and income
Number of subjects: 0
Study 24434160 — intervention group
Group type: EXPERIMENTAL
Intervention: Luoghi di Prevenzione‐Prevention Grounds programme (intervention)
Number of subjects: 989
Study 22496767 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (3 mg kg(‐1); AM(CAFF) trial)
Number of subjects: 12
Study 22496767 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion (AM(PLAC) trial)
Number of subjects: 12
Study 22496767 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion (PM(PLAC) trial)
Number of subjects: 12
Study 19942023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received two individual registered dietitian‐led in‐home education sessions.
Number of subjects: 58
Study 19942023 — intervention group
Group type: COMPARATOR
Intervention: Control group received education material mailings (Visits 2 and 3).
Number of subjects: 58
Study 17445347 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich diet for 1 month
Number of subjects: 30
Study 15340356 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele carriers of the ECE1B C-338A variant
Number of subjects: 401
Study 15340356 — intervention group
Group type: COMPARATOR
Intervention: Control group (aged controls)
Number of subjects: 401
Study 11588025 — intervention group
Group type: EXPERIMENTAL
Intervention: ChOP
Number of subjects: 938
Study 11588025 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP
Number of subjects: 938
Study 11588025 — intervention group
Group type: EXPERIMENTAL
Intervention: fludarabine (FAMP)
Number of subjects: 938
Study 9699585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg intravenously before bypass and 33 mg/hr infusion after operation until the fifth postoperative day
Number of subjects: 20
Study 9699585 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative therapy
Number of subjects: 20
Study 8137335 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day) plus retinyl palmitate (25,000 IU/day)
Number of subjects: 15105
Study 8137335 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15105
Study 2802363 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment with one of three different fixed drug combinations containing isoniazid
Number of subjects: 808
Study 2802363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 108043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethane-1-hydroxy-1,1-diphosphonate (EHDP) 4.4 mmol daily for 12 months
Number of subjects: 9
Study 108043 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 12 months of EHDP treatment
Number of subjects: 9
Study 108043 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDP treatment
Number of subjects: 9
Study 30047159 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 0
Study 28538983 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-fidelity simulation (synthetic anatomy for surgical tasks)
Number of subjects: 0
Study 28538983 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation (deceased donor)
Number of subjects: 0
Study 28538983 — intervention group
Group type: COMPARATOR
Intervention: Control group (SimMan, no surgical anatomy)
Number of subjects: 0
Study 25486415 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-IRIS patients
Number of subjects: 154
Study 25486415 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ART initiation in TB-IRIS patients
Number of subjects: 154
Study 25486415 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-IRIS patients at week 34 post-TB treatment initiation
Number of subjects: 154
Study 25486415 — intervention group
Group type: COMPARATOR
Intervention: Non-TB-IRIS patients
Number of subjects: 154
Study 23041000 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid patients
Number of subjects: 758
Study 23041000 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism
Number of subjects: 758
Study 23041000 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 758
Study 23041000 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical thyroid dysfunction
Number of subjects: 758
Study 16452331 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multivitamin supplementation
Number of subjects: 327